Market Trends of Global Herpes Zoster Infection Treatment Industry
This section covers the major market trends shaping the Herpes Zoster Infection Treatment Market according to our research experts:
Antiviral Drug Segment is Expected to Hold Significant Market Share Over the Forecast Period
The antiviral drug segment holds a significant market share in the herpes zoster infection treatment market and is anticipated to show a similar trend over the forecast period as it reduces viral shedding and accelerates the resolution of symptoms such as reducing pain and developing fast healing. The segment is driven by things like the fact that there are many antiviral drugs for treating herpes zoster infections and that market players keep putting out new products.
According to the study published by UpToDate in August 2022, the effectiveness of topical and systemic antivirals in the prevention of oral herpes discovered that both oral acyclovir (800 to 1600 mg daily) and valacyclovir (500 mg daily) were beneficial in reducing the risk of oral herpes. Because antivirals work well, people will be more likely to use low-concentration acyclovir drugs to make sure they are safe. This will lead to more people using this segment, which will keep growing throughout the time frame of the projection.
As a result of its cost-effectiveness, many companies are engaged in drug development, and the use of acyclovir in herpes zoster is predicted to be significant. For instance, in September 2021, the Indian Patent Office issued a patent to Aurobindo Pharma for its technology for producing valacyclovir, an antiviral medicine sold under the brand name Valtrex in the United States and other countries. Aurobindo's invention is for a better method of preparing medication or pharmaceutically suitable salts. In humans, valacyclovir hydrochloride is used to treat viral diseases such as herpes zoster and genital herpes. Thus, all the aforementioned factors are expected to boost segment growth over the forecast period.
North America is Expected to Hold a Significant Share of the Market Over the Forecast Period
The North American region is expected to hold a major market share of the global herpes infection treatment market, due to the high incidence rate of herpes zoster in North America and readily available medications. The presence of major players involved in the commercialization and development of herpes zoster interventions is a primary factor for the growth of this market in this region.
Major companies are focusing on developing and marketing safe and effective vaccines to treat herpes zoster infection by conducting various clinical trials. For instance, in August 2022, Nobel Pharma started a clinical trial to study the effect of NPC-06 in patients with pain associated with acute herpes Zoster. The study is under Phase 3 of the clinical trial and is expected to be completed by July 2023.
Furthermore, product launches and approval by regulatory bodies support market growth. For instance, in July 2021, GlaxoSmithKline plc reported that the United States Food and Drug Administration (FDA) approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted), to prevent herpes zoster in adults aged 18 and above who are at higher risk of developing the disorder due to immunodeficiency.
Hence, the rising burden of infections due to the herpes zoster virus, coupled with the rising awareness and new product launches, is expected to boost market growth over the forecast period.
